Pharma News
FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec
![](https://meefro.com/wp-content/uploads/2024/01/FDA-Grants-Fast-Track-Breakthrough-Designations-to-CG-Oncology-Incs-780x470.png)
Cretostimogene grenadenorepvec (CG0070) is currently being evaluated for the treatment of patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors.
Source link
#FDA #Grants #Fast #Track #Breakthrough #Designations #Oncology #Incs #Cretostimogene #Grenadenorepvec